Cargando…
Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?
The association between cardiovascular (CV) disease and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is well documented. The recent work by Massicotte-Azarniouch et al. confirms the risk and adds to the existing evidence by describing the highest risk in the first 3 months...
Autores principales: | Floyd, Lauren, Morris, Adam D, Woywodt, Alexander, Dhaygude, Ajay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967680/ https://www.ncbi.nlm.nih.gov/pubmed/35371453 http://dx.doi.org/10.1093/ckj/sfac009 |
Ejemplares similares
-
Rituximab in the treatment of primary FSGS: time for its use in routine clinical practice?
por: Morris, Adam D, et al.
Publicado: (2023) -
The impact of COVID-19 pandemic on patients with ANCA associated vasculitis
por: Kant, Sam, et al.
Publicado: (2020) -
Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis
por: Floyd, Lauren, et al.
Publicado: (2023) -
Frailty assessment in ANCA-associated vasculitis: current evidence and remaining uncertainties
por: Wang, Choon Ying, et al.
Publicado: (2022) -
Have we missed AINything? Acute interstitial nephritis in SARS-CoV-2 infection and vaccination
por: Storrar, Joshua, et al.
Publicado: (2022)